Skip to main content
ClinicalTrials.govrestricted

A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML

ClinicalTrials.gov study NCT05199051. IPD Sharing: Not stated. Countries: 1. Publications: 0.

ShareScore

24/100

Overall dataset sharing score

Score breakdown

These five areas show where the dataset supports — or may limit — practical reuse.

Stewardship
12
Harmonization
8
Access
0
Reuse readiness
0
Engagement
4

Topics